What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Enterprise Value?

Recursion Pharmaceuticals, Inc. Class A Common Stock's Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.

What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Diluted EPS (TTM)?

Recursion Pharmaceuticals, Inc. Class A Common Stock's Diluted EPS (TTM) is -0.97, based on as-reported figures from SEC (XBRL) filings.

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Financial Statements

Recursion Pharmaceuticals, Inc. Class A Common Stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00PQ4XJ54

XNAS · usd

3.51▼ 0.13 (-3.44%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close3.63

Day's Range3.41 – 3.70

52-Week Range2.77 – 7.18

Volume28.9M

Avg Volume15.8M

Share Statistics

Shares Outstanding

Employees600

ExchangeXNAS

Listed2021-04-16

Share count as of July 31, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)

What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Market Cap?: Recursion Pharmaceuticals, Inc. Class A Common Stock's Market Cap is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Enterprise Value?: Recursion Pharmaceuticals, Inc. Class A Common Stock's Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Price / Sales?: Recursion Pharmaceuticals, Inc. Class A Common Stock's Price / Sales is 34.2×, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's EV / Revenue?: Recursion Pharmaceuticals, Inc. Class A Common Stock's EV / Revenue is 24.5×, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's EV / EBITDA?: Recursion Pharmaceuticals, Inc. Class A Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Revenue (TTM)?: Recursion Pharmaceuticals, Inc. Class A Common Stock's Revenue (TTM) is $54.9M, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Net Income (TTM)?: Recursion Pharmaceuticals, Inc. Class A Common Stock's Net Income (TTM) is -$518.9M, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's EBITDA?: Recursion Pharmaceuticals, Inc. Class A Common Stock's EBITDA is -$465.6M, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's Diluted EPS (TTM)?: Recursion Pharmaceuticals, Inc. Class A Common Stock's Diluted EPS (TTM) is -0.97, based on as-reported figures from SEC (XBRL) filings.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock's EBITDA Margin?: Recursion Pharmaceuticals, Inc. Class A Common Stock's EBITDA Margin is -848.9%, based on as-reported figures from SEC (XBRL) filings.